Saturday 17 October 2026
Export ATRA’s income statement to Excel — free account
Atara Biotherapeutics, Inc.
ATRA Healthcare Biotechnology
Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024. In the quarter to June 2026, revenue fell 96.4%, EPS fell 260.0% and free cash flow grew 52.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
9.18
0.47
−4.87%
Follow ATRA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
5.72 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Piotroski F-Score |
5 | 5 | 2 | — | — | — | — | — | — | — |
P/S ratio |
1.88 | 0.77 | 5.93 | 5.26 | 72.58 | — | — | — | — | — |
Altman Z-Score |
(125.91) | (28.18) | (22.28) | (7.09) | (1.32) | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(315.39) | (71.22) | — | (15.37) | (9.62) | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/Operating CF |
(39.83) | (4.07) | (1.01) | (5.88) | (43.08) | — | — | — | — | — |
Beneish M-Score |
16.88 | 7.89 | — | 11.96 | — | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 2.64 | 5.28 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 2.64 | 5.28 | — | — | — | — | — |
EV/Sales |
1.81 | 0.44 | (0.12) | 1.44 | 54.33 | — | — | — | — | — |
EV/EBITDA |
5.71 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(4.29) | (0.83) | 0.01 | (0.34) | (5.01) | — | — | — | — | — |
EV/FCF |
(4.36) | (0.83) | 0.01 | (0.33) | (4.78) | — | — | — | — | — |
Quick Ratio |
0.65 | 0.33 | 0.60 | 3.59 | 3.52 | 6.06 | 7.06 | 7.75 | 6.02 | 26.45 |
Current Ratio |
0.82 | 0.48 | 0.72 | 3.74 | 3.64 | 6.31 | 7.43 | 8.04 | 6.23 | 26.93 |
Net Debt/EBITDA |
(0.22) | 0.54 | 0.19 | 0.89 | 1.13 | 1.67 | 0.89 | 1.32 | 1.39 | 3.27 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
1.87 | 0.94 | 0.03 | 0.15 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
(1.56) | 0.80 | 0.70 | 1.18 | 0.65 | 0.59 | 0.81 | 0.78 | 0.73 | 0.76 |
Capex/Depreciation |
0.40 | (0.05) | (0.21) | (0.63) | (0.95) | (0.49) | (0.97) | (19.45) | (11.99) | (1.02) |
Interest Coverage |
9.46 | (18.08) | (52.22) | (752.05) | — | — | — | — | — | (36.88) |
| (48.15%) | 86.92% | (2,014.86%) | (112.39%) | (91.69%) | (81.43%) | (92.43%) | (89.29%) | (55.37%) | (27.79%) | |
| 50.55% | (62.20%) | (101.91%) | (54.06%) | (64.41%) | (65.86%) | (79.20%) | (75.69%) | (49.61%) | (26.85%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (587.08%) | (510.45%) | (656.28%) | 0.00% |
Return on Tangible Assets |
(1,239.59%) | 124.88% | 756.49% | (102.62%) | (102.26%) | (62.46%) | (100.19%) | (65.90%) | (63.33%) | (31.10%) |
Average Days of Receivables |
3.79 | 4.20 | 1,452.17 | 230.93 | 17.69 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
31.00% | 117.48% | 2,622.01% | 428.69% | 1,386.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
21.74% | 30.93% | 593.82% | 112.55% | 387.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
8.07% | 20.94% | 529.41% | 84.69% | 264.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.20) | (1.42) | (3.20) | 0.14 | 0.13 | — | — | — | — | — |
Graham Number |
0.00 | 61.57 | 185.81 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
17.47% | (97.45%) | (545.83%) | (67.99%) | (23.03%) | — | — | — | — | — |
Free Cash Flow Yield |
(22.07%) | (69.19%) | (381.99%) | (82.09%) | (15.65%) | — | — | — | — | — |
Revenue per Share |
9.63 | 17.22 | 2.02 | 15.58 | 5.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(4.06) | (9.18) | (45.56) | (66.29) | (58.86) | (61.09) | (114.81) | (102.59) | (73.25) | (52.23) |
Capex per Share |
0.08 | (0.03) | (0.28) | (1.03) | (2.82) | (1.53) | (2.71) | (20.50) | (16.94) | (2.63) |
Free Cash Flow per Share |
(3.99) | (9.21) | (45.84) | (67.32) | (61.68) | (62.62) | (117.53) | (123.09) | (90.19) | (54.86) |
Cash per Share |
0.68 | 5.69 | 12.25 | 59.56 | 99.09 | 169.27 | 126.35 | 176.80 | 139.21 | 222.64 |
Shareholders Equity per Share |
(3.07) | (12.99) | (23.43) | 31.04 | 74.63 | 156.25 | 141.69 | 193.37 | 148.90 | 220.77 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(3.07) | (12.99) | (23.43) | 31.04 | 74.63 | 156.25 | 141.69 | 193.37 | 148.90 | 220.77 |
Free Cash Flow |
(49.99) | (68.96) | (194.17) | (274.62) | (231.10) | (185.27) | (241.20) | (215.70) | (107.73) | (63.04) |
Working Capital |
(2.71) | (69.68) | (40.36) | 216.16 | 278.84 | 440.37 | 236.25 | 281.51 | 144.54 | 250.88 |
Capital Expenditures |
0.95 | (0.25) | (1.20) | (4.19) | (10.58) | (4.51) | (5.57) | (35.92) | (20.23) | (3.02) |
Net Current Asset Value |
(46.52) | (141.49) | (162.87) | 45.30 | 196.11 | 397.49 | 220.83 | 268.51 | 132.28 | 250.38 |
EV/EBIT |
6.09 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
(0.01) | 0.00 | 0.14 | 0.07 | 0.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
6.33 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
32.53 | 3.72 | 1.46 | 1.06 | 0.21 | 0.18 | 0.11 | 0.03 | 0.04 | 0.91 |
Cash ROIC |
166.53% | 126.21% | 410.00% | (74.30%) | (35.51%) | (19.24%) | (43.85%) | (33.25%) | (31.30%) | (12.37%) |
Accounts Receivable Turnover |
88.32 | 7.25 | 0.23 | 3.09 | 18.19 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
9.44 | 5.22 | 1.68 | 1.20 | 0.93 | 1.31 | 1.39 | 0.41 | 0.11 | 0.18 |
Inventory Turnover |
0.00 | 2.06 | 1.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
2.19 | 75.87 | 151.32 | 172.15 | 557.06 | 263.31 | 358.61 | 359.01 | 5,616.65 | 2,647.44 |
Days of Inventory on Hand |
0.00 | 185.11 | 398.68 | 39.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.37 | 17.80 | 37.16 | 20.60 | 1.12 | 1.12 | — | — | — | — |
Average Payables |
2.25 | 4.03 | 5.28 | 12.12 | 12.24 | 7.54 | 5.84 | 9.22 | 8.74 | 2.11 |
Average Inventory |
— | 10.18 | 5.65 | — | — | — | — | — | — | — |
Average Assets |
64.67 | 137.30 | 270.96 | 422.27 | 528.12 | 465.53 | 367.39 | 304.81 | 240.85 | 294.44 |
Average Common Equity |
(67.89) | (98.26) | 13.70 | 203.13 | 370.98 | 376.56 | 314.82 | 258.36 | 215.80 | 284.42 |
Columns are period end dates